Physician profile
Kimberly Halla
NPI 1427406719
$331,845.86
in general payments reported to CMS, 2019-2025
23 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44K · 2022: $74K · 2023: $63K · 2024: $68K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Travel and Lodging: $61K · Consulting Fee: $19K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Food and Beverage: $8,973 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,852.50 |
| Travel and Lodging | $61,327.57 |
| Consulting Fee | $18,631.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,191.25 |
| Food and Beverage | $8,973.42 |
| Education | $172.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $139,008.84 | 2021-2025 | Jemperli, Zejula |
| Eisai INC. | $92,555.06 | 2021-2025 | |
| Genmab U.S., INC. | $50,315.47 | 2021-2025 | Tivdak, Epkinly |
| Merck Sharp & Dohme LLC | $22,314.95 | 2021-2025 | Keytruda, Lynparza |
| Pfizer INC. | $14,369.53 | 2024-2025 | |
| Seagen INC. | $10,478.58 | 2021-2025 | Tivdak |
| Astrazeneca Pharmaceuticals LP | $1,050.74 | 2021-2025 | Lynparza |
| Intuitive Surgical, INC. | $572.10 | 2023 | Da Vinci Surgical System |
| Myriad Genetic Laboratories, INC. | $434.74 | 2021-2025 | Myrisk |
| Abbvie INC. | $215.15 | 2024-2025 | |
| Immunogen, INC. | $125.00 | 2024 | Elahere |
| Astellas Pharma US INC | $116.02 | 2024 | Veozah |
| Ipsen Biopharmaceuticals, INC | $47.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.72 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $39.78 | 2023 | Imbruvica, Epkinly |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| On Target Laboratories, INC | $38.41 | 2025 | Cytalux |
| Genentech USA, INC. | $21.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.68 | 2021 | |
| Kyowa Kirin, INC. | $18.76 | 2021 | |
| Genzyme Corporation | $16.30 | 2021 | |
| Myovant Sciences INC. | $15.54 | 2021 | |
| Janssen Biotech, INC. | $12.53 | 2021 | |
| Amgen INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Halla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.